   
 
 
 
CLINICAL STUDY PROTO COL  
ALK3831-A308 
EudraCT 2017-000918-36 
 
Study Title: A Phase [ADDRESS_1173476] of 
ALKS  3831 in Subjects with Schizophrenia, 
Schizophreniform Disorder, or Bipolar I Disorder  
Document Date:  Amendment 3.0: 09 May  2019 
Amendment 2.0: 10 Jan  2018 
Amendment 1.0: 12 Sep 2017 
Original Protocol: 01 Feb 2017 
Sponsor: Alkermes, Inc.  
[ADDRESS_1173477]  
Waltham, MA [ZIP_CODE] 
[LOCATION_003] 
 
CONFIDENTIAL  
Information and data in this protocol contain trade secrets and privileged or confidential information, 
which is the property of Alkermes, Inc. No person is authorized to make it public without the written permission of Alkermes, Inc. These restrictions or disclosures will apply equally to all future information 
supplied to you that is indicated as privileged or confidential.  
 
  

Alkermes, Inc.  
Protoc
ol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 3 of 49 2. SYNOPSIS
Name [CONTACT_790]/Company:  Alkermes, Inc.  
Name [CONTACT_791]:  ALKS  3831  
Name [CONTACT_3261]:  Olanzapi[INVESTIGATOR_582404] S tudy:  A Phase [ADDRESS_1173478] of ALKS  3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or 
Bipolar I Disorder  
Investigator(s): This is a multinational multicenter study.  
Study Period:  
Estimated date of first subject’s consent: Q2 [ADDRESS_1173479]’s last visit: Q4 202 2 Phase of Development:  3 
Objective : The primary objective of this study is to evaluate the long -term safety, tolerability, and 
durability of treatment effect of ALKS  3831 in subjects with schizophrenia, schizophreniform disorder, 
or bipolar I disorder. 
Methodology:  This is a multicenter, open -label study to evaluate the long-term safety, tolerability, and 
durability of treatment effect of ALKS  [ADDRESS_1173480] completed the antecedent studies (ALK3831-A304, 
ALK3831-A306, or ALK3831-A307) within the past 7 days will be eligible to enroll in this study.  
Subjects enrolled in the study will be started on the same olanzapi[INVESTIGATOR_844300]. Available doses of ALKS  3831 will be 5, 10, 15, and 20 mg olanzapi[INVESTIGATOR_667858] 10 mg samidorphan (henceforth to be r eferred to as  5/10, 10/10, 15/10, and 20/10 mg). 
Subjects may be titrated to a different dose after the start of the study at the Investigator’s discretion. Dosing will be flexible throughout the study; however, frequent adjustments are discouraged. Dose 
adjustments will only be performed on- site at the study center. Subjects requiring dose adjustments 
between scheduled visits will need to arrange an unscheduled visit.  
Safety assessments will include adverse event (AE) monitoring, clinical laboratory testin g, vital signs, 
body weight, electrocardiograms (ECGs), and the Columbia- Suicide Severity Rating Scale (C -SSRS). 
Psychiatric symptoms will be evaluated using the Clinical Global Impressions- Severity (CGI -S) scale. 
Additional assessments will include Impact  of Weight on Quality of Life-Lite Questionnaire 
(IWQOL -Lite).  A schematic summarizing study design is presented below.  
Study Design Schematic:  

  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 4 of 49 Number of Subjects Planned:  Approximately 500 subjects  
Main Criteria for Inclusion:  Subjects will have completed the treatment period in one of the 
following antecedent studies within 7  days: ALK3831-A304, ALK3831-A306, or ALK3831-A307. 
Subjects will have potential to benefit from ALKS  [ADDRESS_1173481] -menopausal.  
Main Criteria for Exclusion:  Subjects may be excluded based on positive tests for drugs of abuse at 
study entry, a ny finding that would compromise the subject’s safety or their ability to fulfill the study 
requirements, pregnancy or breastfeeding, or employment by (or relationship to an employee of) the 
study sponsor, clinical research organization, or study site. 
Investigational Product, Dosage, Duration , and Mode of Administration:  ALKS  [ADDRESS_1173482] is enrolled, the duration of participation in this study will vary . 
Reference Therapy , Dosage, Duration, and Mode of A dministration:  None  
Duration of Study:  The total study duration will be up to 49 months, including a treatment period of 
24 to 48 months and a 4- week safety Follow-up period.  
Criteria for Evaluation:  
Safety and Tolerability:  The following parameters will be collected to measure safety and tolerability 
throughout the study:  
• AEs (including cli nically significant abnormal ECG findings)  
• Vital signs (oral temperature, respi[INVESTIGATOR_697], blood pressure, and heart rate)  
• Weight and waist circumference  
• Clinical laboratory parameters (bio chemistry, hematology, and urinalysis)  
• C-SSRS  
Efficacy : Throughout the study, CGI -S scores will be collected to measure the durability of treatment 
effect . 
Other:  Throughout the study, IWQOL -Lite scores will be collected to obtain information regarding 
subject experience.  
Endpoints:  
Safety  and Tolerability Endpoints : 
• Incidence of AEs  
• Percent change from baseline in body weight by [CONTACT_765]  
• Absolute change from baseline in body weight by [CONTACT_765]  
• Change from baseline in waist circumference by [CONTACT_844318]:  
• Change from baseline in CGI- S by [CONTACT_765]  
• Time to discontinuation  
• Change from baseline in IWQOL -Lite score by [CONTACT_667885]:  In general, summary statistics (n, mean, standard deviation, median, minimum 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 5 of 49 and maximum for continuous variables, and number [%] of subjects in each category for categ orical 
variables) will be provided for all variables. Source data for the summary tables and statistical analyses 
will be presented as subject data listings.  
Study Populations:  The S afety Population will include all enrolled subjects who receive at least 
1 dose of study drug. All analyses will be conducted using the S afety Population.  
Efficacy  Analyses: Changes from baseline in CGI -S and IWQOL -Lite scores  will be summarized 
using descriptive statistics. Th e time to discontinuation will be estimated using the Kaplan -Meier (KM) 
method and the KM plot will be provided.  
Safety Analyses:  All safety assessments will be summarized using descriptive statistics. All safety 
analyses will be based on observed data only, and no missing values will be imputed. Reported AE terms will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
summarized by [CONTACT_582452]. Serious adverse events (SAEs) and 
AEs leading to study discontinuation will also be summarized. 
Observed values and change from baseline in laboratory parameters and vital signs  will be summarized 
by [CONTACT_15449]. The number and percentage of subjects who have met potentially clinically significant 
criteria at any post baseline visit will be summarized for laboratory  and vital signs.  The number and 
percentage of subjects with shifts in laboratory parameters will be summarized. Supporting listings will 
be provided. The number and percentage of subject s with C -SSRS assessments of suicidal ideation and 
behavior will also be summarized.  
Concomitant medication use will be summarized by [CONTACT_667887] (WHO ATC) classification system. Listings will be provided for all concomitant 
medications.  
Sample Size Considerations:  No formal sample size calculation will be performed for this extension 
study. A sample size of approximately 500 is based on the estimated number of subjects who are 
expected to roll over from the antecedent Phase 3 studies (ALK3831-A304, ALK3831-A306, and ALK3831-A307).  
 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173483] Withdrawal  ....................................................................................................16  
7.4. Replacement of Subjects  .............................................................................................16  
8. STUDY DESIGN  .......................................................................................................17  
8.1. Overall Study Design and Plan  ...................................................................................17  
8.2. Schedule of Visits and Assessments ...........................................................................18  
8.3. Study Procedures Descriptions ...................................................................................21  
8.3.1.  Informed Consent .......................................................................................................21  
8.3.2.  Eligibility Review  .......................................................................................................21  
8.3.3.  Demographics and Medical / Psychiatric History  ......................................................[ADDRESS_1173484] Circumference  ...............................................................................22  
8.3.8.  Structured Interviews and Questionnaires ..................................................................22  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 7 of 49 [IP_ADDRESS].  Safety Assessments  .....................................................................................................22  
[IP_ADDRESS].  Psychiatric/Quality of Life Assessments  ....................................................................22  
8.3.9.  Laboratory Assessments  .............................................................................................22  
[IP_ADDRESS].  Drug Testing  ...............................................................................................................22  
[IP_ADDRESS].  Hematology, Biochemistry, and Urinalysis  ................................................................23  
[IP_ADDRESS].  Urine Pregnancy Testing  ............................................................................................[ADDRESS_1173485]  ........................................................................................25  
8.3.12.  Adverse Event Monitoring .........................................................................................25  
8.4. Study Requirements and Restrictions .........................................................................25  
8.4.1.  Contraception and Pregnancy .....................................................................................25  
8.4.2.  Prohibited Medications ...............................................................................................26  
8.4.3.  Permitted Medications  ................................................................................................26  
8.4.4.  Pain Management  .......................................................................................................27  
8.4.5.  Fasting .........................................................................................................................27  
8.4.6.  Other Restrictions and Requirements .........................................................................27  
9. TREATMENT OF SUBJECTS ..................................................................................29  
9.1. Study Drug Dose and Administration  .........................................................................29  
9.2. Treatment Adherence  ..................................................................................................29  
9.3. Randomization/Method of Assigning Subjects to Treatment .....................................29  
9.4. Blinding ......................................................................................................................29  
10. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................30  
10.1.  Study Drug  ..................................................................................................................30  
10.2.  Packaging and Labeling  ..............................................................................................30  
10.3.  Storage ........................................................................................................................30  
10.4.  Accountability .............................................................................................................30  
10.5.  Handling and Disposal ................................................................................................30  
11. ASSESSMENT OF EFFICA CY ................................................................................32  
11.1.  Efficacy Endpoints ......................................................................................................32  
12. ASSESSMENT OF PHARMACOKINETICS  ...........................................................33  
13. ASSESSMENT OF SAFETY  .....................................................................................34  
13.1.  Safety Endpoints  .........................................................................................................34  
13.2.  Definition of Adverse Event .......................................................................................34  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 8 of 49 13.3.  Definition of Serious Adverse Event ..........................................................................34  
13.4.  Relationship to Study Drug ........................................................................................35  
13.5.  Monitoring and Recording of Adverse Events ...........................................................36  
13.6.  Reporting of Serious Adverse Events and Pregnancy ................................................37  
14. STATISTICS  ..............................................................................................................38  
14.1.  Sample Size Considerations .......................................................................................38  
14.2.  General Statistical Methodology  ................................................................................38  
14.2.1.  Study Population .........................................................................................................38  
[IP_ADDRESS].  Safety Population ........................................................................................................[ADDRESS_1173486] ACCESS TO SOU RCE DATA/DOCUMENTS .........................................[ADDRESS_1173487]/Independent Ethics Committee  ......................................[ADDRESS_1173488] of the Study ......................................................................................42  
17.3.  Written Informed Consent ..........................................................................................42  
18. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645]  .......................................................44  
18.1.  Data Capture  ...............................................................................................................44  
18.2.  Inspection of Records .................................................................................................44  
18.3.  Retention of Records ..................................................................................................44  
18.4.  Use of  Information and Publication Policy ................................................................45  
19. REFERENCES  ...........................................................................................................46  
20. APPENDIX A: PARTIAL LIST OF PROHIBITED C YTOCHROME P450 
(CYP) 3A INHIBITORS AND INDUCERS  ..............................................................47  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 9 of 49 21. APPENDIX B: PARTIAL LIST OF CYP1A2 MODERATE -TO-STRONG 
INHIBITORS AND MODER ATE INDUCERS  ........................................................48  
22. APPENDIX C: PARTIAL LIST OF MEDICATIONS KNOWN TO BE 
ASSOCIATED WITH PROL ONGED QTC INTERVAL AND TORSADE 
DE POINTES  ..............................................................................................................[ADDRESS_1173489] OF TABLES 
Table 1:  Study Contact [CONTACT_7171] ...........................................................................................2  
Table 2:  List of Abbreviations and Definition of Terms  ..........................................................10  
Table 3:  Schedule of Assessments  ............................................................................................19  
Table 4:  Clinical Laboratory Assessments  ...............................................................................24  
Table 5:  Adverse Event Causality Guidelines  ..........................................................................36  
Table 6:  Partial List of CYP3A Inhibitors and Inducers ...........................................................47  
Table 7:  Partial List of CYP1A2 Inhibitors and Inducers .........................................................48  
Table 8:  Partial List of Medic ations Known to Be Associated with Prolonged QTc 
Interval and Torsade de Pointes ..................................................................................[ADDRESS_1173490] OF FIGURES  
Figure  1: Study Design Schematic  .............................................................................................[ADDRESS_1173491] OF ABBREVIATIONS  
Table 2: List of Abbreviations and Definition of Terms  
Abbreviation or Term  Full Form or Definition  
AE Adverse event  
ANC  Absolute neutrophil count  
ATC  Anatomical Therapeutic Chemical [classification system]  
CGI-S Clinical Global Impressions -Severity  
CRO  Clinical Research Organization  
CSA Clinical Study Agreement  
C-SSRS  Columbia- Suicide Severity Rating Scale  
CYP  Cytochrome P450 
ECG  Electrocardiogram  
eCRF  Electronic case report form  
ET Early termination  
GCP  Good Clinical Practice  
HbA1c  Hemoglobin A1c 
ICF Informed consent form  
ICH International Council on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IWQOL -Lite Impact of Weight on Quality of Life- Lite 
KM Kaplan -Meier  
MedDRA  Medical Dictionary for Regulatory Activities  
PI [INVESTIGATOR_844301] -emergent adverse event  
WHO World Health Organization 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 11 of 49 5. INTRODUCTION 
5.1. Background  
Olanzapi[INVESTIGATOR_667839] 20 years as a treatment for schizophrenia 
and bipolar I disorder (see local olanzapi[INVESTIGATOR_667840]) and is regarded as a highly effective treatment 
with demonstrated antipsychotic efficacy and decreased incidence of extrapyramidal symptoms. 
However, the greater antipsychotic efficacy of olanzapi[INVESTIGATOR_844302] ( Allison et al, 1999; Leucht et al, 2013; Lieberman et al, 2005; Meyer et al, 
2008; Wirshing et al, 1999). Olanzapi[INVESTIGATOR_844303] a second- line treatment in 
patients early in illness according to the  Schizophrenia Patient Outcomes Research Team 
(PORT) treatment guidelines  (Buchanan et al, 2010) . This is largely due to the fact that 
olanzapi[INVESTIGATOR_050]-induced weight gain and metabolic risk is especially pronounced in patients who are early in illness for both schizophrenia and bipolar disorder ( Correll et al, 2014). 
Alkermes is developi[INVESTIGATOR_182000] 3831 as a fixed-dose combination of olanzapi[INVESTIGATOR_249674] 
(a µ-opi[INVESTIGATOR_2634]), for the treatment of schizophrenia designed to combine the 
antipsychotic efficacy of olanzapi[INVESTIGATOR_139731] a reduced risk of weight gain and associated metabolic 
deficits . The novel combination of olanzapi[INVESTIGATOR_667846] 3831 has the potential 
to deliver the therapeutic benefits of olanzapi[INVESTIGATOR_844304].  
Development of ALKS 3831 as a fixed -dose combination of olanzapi[INVESTIGATOR_844305]/risk profile of olanzapi[INVESTIGATOR_249677] a significant clinical need for patients that are currently  forced to choose between treatment efficacy and 
safety.  Four Phase 3 studies ( ALK3831-A303, ALK3831-A304, ALK3831-A305, and 
ALK3831-A306) are ongoing to assess the efficac y, associated weight changes, and safety of 
ALKS  3831 in subjects with schizophrenia. One Phase 3 study ( ALK3831-A307) is planned to 
begin enrollment in [ADDRESS_1173492] of ALKS  3831 compared to olanzapi[INVESTIGATOR_844306], schizophreniform, or bipolar I disorder with a recent onset of symptoms and early in medical treatment.  
5.2. Study Drugs  
In this study a fixed dose combination of olanzapi[INVESTIGATOR_249678] a 
single bilayer tablet. The following sections provide an overview of samidorphan and 
olanzapi[INVESTIGATOR_050]. Detailed information about the study drugs can be found in the current ALKS  3831 Investigator’s Brochure . 
  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173493]. It is currently being investigated in combination with olanzapi[INVESTIGATOR_844307] (ALKS 3831) and in combination with buprenorphine for the 
treatment of major depressive disorder (ALKS 5461). Based on its chemical structure, samidorphan is considered a Schedule II controlled substance according to the US Drug 
Enforcement Agency and will require proper handling (see Section  10.5). At least [ADDRESS_1173494] been conducted to date, eight of which included subjects that 
received sam idorphan alone (not in combination with another product). Overall, over 
[ADDRESS_1173495] been exposed to samidorphan as a single agent or in combination with olanzapi[INVESTIGATOR_667850]. Commonly reported adverse events (AEs) observed across all studies included nausea, fatigue, and somnolence. 
Overall, no trends or clinically meaningful changes have been observed in clinical laboratory 
analytes, vital sign parameters, or electrocardiogram (ECG) data.  
5.2.2. Olanzapi[INVESTIGATOR_667851] 20 years as a treatment f or schizophrenia 
and bipolar I disorder (see local olanzapi[INVESTIGATOR_667840]).  The safety  and tolerability profile of 
olanzapi[INVESTIGATOR_844308], and AE labeling is supported by [CONTACT_844319] [ADDRESS_1173496]- marketing experience (see local olanzapi[INVESTIGATOR_667840]) . Commonly 
reported AEs consistent across al l or most dosage forms in short- term, placebo controlled trials 
include somnolence, constipation, dry mouth, accidental injury, weight gain, postural hypotension, dizziness, asthenia, fever, and abnormal gait. 
5.3. Study Rationale  
This Phase 3 study is an extension study (for antecedent studies ALK3831-A304, 
ALK3831-A306, and  ALK3831-A307) that will evaluate the long -term safety, tolerability, and 
durability of treatment effect of ALKS  [ADDRESS_1173497] treatment durations evaluated so far (up to 5.5 years). Information regarding non- clinical and clinical studies completed to date with 
ALKS  3831 is available in the current version of the Investigator’s Brochure . 
  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 13 of 49 5.4. Dose Rationale  
All s ubjects will receive ALKS  3831. The doses of ALKS 3831 will be 5, 10, 15, and 20 mg 
olanzapi[INVESTIGATOR_667832] 10 mg samidorphan (henceforth to be referred to as 5/10, 10/10, 
15/10, and 20/10 mg). These doses represent the intended therapeutic doses of ALKS [ADDRESS_1173498] that data from Study ALK3831-302 demonstrated no correlation between the ratio of samidorphan/olanzapi[INVESTIGATOR_844309] [ADDRESS_1173499] of olanzapi[INVESTIGATOR_667859]. The antipsychotic efficacy seen in stable subjects 
treated in study ALK3831-302 was similar between ALKS 3831 and olanzapi[INVESTIGATOR_667860]. Based on the available data from the completed studies in healthy 
volunteers ( ALK33 -301) and in subjects with schizophrenia (ALK3831-302) , subjects treated 
with ALKS [ADDRESS_1173500] been shown to gain less weight compared to subjects treated  with 
olanzapi[INVESTIGATOR_582419]. In ALK3831-302, the prevention of weight gain persisted  during the 3 month 
ALKS 3831 treatment period. 
The important identified risks associated with the use of olanzapi[INVESTIGATOR_667861], glucose 
dysregu lation , and dyslipi[INVESTIGATOR_035]. For additional information on the known risks of olanzapi[INVESTIGATOR_050], 
see the local label. The safety profile of ALKS 3831 is consistent with that of olanzapi[INVESTIGATOR_050] (see 
local label). In study ALK3831-302, the only adverse events reported with ALKS 3831 treatment 
occurring in ≥5% of subjects and at ≥[ADDRESS_1173501] common adverse events noted in clinical studies in >2% of subjects with  ALKS [ADDRESS_1173502] abnormal (see current ALKS 3831 Investigator’s 
Brochure ). In summary, data from the completed ALKS [ADDRESS_1173503] is willing and able to give informed consent/assent as per local requirements
2. Subject agrees to use an acceptable method of contraception during the study and until
[ADDRESS_1173504] met  the eligibility  criteria of the antecedent study at the time of enrollment in  the
antecedent study and completed  the treatment period in one of the following antecedent
studies within 7  days: ALK3831-A304, ALK3831-A306, or ALK3831-A307
7.2. Subject Exclusion Criteria  
Each subject must not meet any of the following criteria  to be qualified to participate in this 
study.  
1.Subject has any finding that in the view of the investigator or medical monitor wouldcompromise the safety of the subject or affect his/her ability to fulfill the protocol visit
schedule or visit requirements
2. Subject has a positive test for drugs of abuse (see Section  [IP_ADDRESS]) at study entry
3. Subject is currently pregnant. breastfeeding or is planning to become pregnant during the
study or within [ADDRESS_1173505] is employed by [CONTACT_43421], the Investigator or study site (permanent, temporary
contract worker, or designee responsible for the conduct of the study) or is imme diate
family
1 of an Alkermes, clinical research organization , or study site employee
5. If in the opi[INVESTIGATOR_689] (and/or Sponsor) is unsuitable for enrollment in the
study
[ADDRESS_1173506] 
has an absolute neutrophil count (ANC) < 1.0 × 103 per µL or Hemoglobin A1c (HbA1c) ≥6.5% 
at any time, the P I (or designee) should discontinue the subject from participation immediately. 
Reasons for discontinuation include: 
• Adverse Event  
• Lack of E fficacy  
• Lost to Follow-up 
• Withdrawal by [CONTACT_27720]  
• Protocol Deviation (including non-compliance with study drug or study procedures)  
• Pregnancy  
• Study Terminated by S ponsor 
• Other  
If a subject withdraws from the study for any reason , any ongoing AEs will be followed until 
resolution, until deemed stable by [CONTACT_737], or until the subject is deemed by [CONTACT_844320]-up. If, in the opi[INVESTIGATOR_689] , it is necessary to 
monitor a subject beyond the safety follow-up visit, the follow-up period may be extended as 
necessary. In such instances, the Sponsor and I nvestigator will agree to an accep table follow -up 
schedule.  
In the event that a subject chooses to withdraw from the study, the Investigator should make a reasonable effort to ascertain the reason(s) for withdrawal, while fully respecting the subject’s 
rights. Subjects who terminate the treatment early (prior to Visit 25) will complete an early termination (ET) visit and the 4-week Safety Follow-up period. The ET visit should be scheduled 
as close as possible to the subject’s last dose and will mimic the assessments sche duled to be 
conducted at the E OT Visit . If the subject fails or refuses to return to the study center, an attempt 
must be made to contact [CONTACT_844321]. All data collected over the telephone must be documented and kept in the subject’s record. 
The Investigator must maintain a record of all subjects who fail to complete the study. T he 
reason for study discontinuation will be documented and made on the appropriate electronic  case 
report form (e CRF ). If a subject is lost to follow -up, a reasonable attempt to contact [CONTACT_667891]. 
7.4. Replacement of Su bjects 
Subjects who withdraw from the study will not be replaced.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173507] completed the antecedent studies 
(ALK3831- A304, ALK3831- A306, or ALK3831- A307) within the past 7  days will be eligible to 
enroll in this study.  
Subjects enrolled in the
 study will be started on the same olanzapi[INVESTIGATOR_844310]. Available doses of ALKS  3831 will be  5/10, 
10/10, 15/10, and 20/10 mg. Subjects may be titrated to a different dose afte r the start of the 
study at the Investigator’s discretion. Dosing will be flexible throughout the study; however, 
frequent adjustments are discouraged. Dose adjustments will only be performed on- site at the 
study center. Subjects requiring dose adjustments between scheduled visits will need to arrange 
an unscheduled visit. 
Safety assessments will include AE monitoring, clinical laboratory testing, vital signs, body 
weight, ECGs , and the Columbia- Suicide Severity Rating Scale (C -SSRS). Psychiatric 
symptoms w ill be evaluated using the CGI -S scale. Additional assessments will include Impact 
of Weight on Quality of Life -Lite Questionnaire (IWQOL -Lite).   
The duration of the treatment period will vary by [CONTACT_1130], between 24 and 48 months, or until regulatory actio n; duration will vary by [CONTACT_1130]. The study completion is targeted for the [ADDRESS_1173508] is enrolled, the end date of the study will be set to occur 24 
months later (approximately the 4th quarter of 2022), and subjects will be informed of the target 
completion date. The total study duration will be up to [ADDRESS_1173509]’s last visit.  
Figure  1: Study Design Schematic  
 

  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173510] to reschedule.  
Premature discontinuation procedures are provided in Section  7.3. 
Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 19 of 49 Table 3: Schedule of Assessments 
Visit s 1-25b Treatment Perioda Follow -up 
Perioda 
Transition  
from 
Previous  
Studyc Monthly 
Visitsd Quarterly  
Visits  EOT/  
ET Safety 
Follow -up 
Visite 
1 2, 3, 5, 6, 8, 
9, 11, 12, 
14, 15, 17, 
18, 20, 21, 
23, 24  4, 7, 10, 13, 
16, 19, 22, 
25  
No later than 
Visit 4 9 No later 
than Visit 
50 Visit s 26-50b 
— 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 
48 28, 31, 34, 37, 40, 43, 
46 
Qualification/ Safety Assessments  
Informed Consent  X     
Eligibility  Review  X     
Urine Pregnancy Testing (all 
women)  X X X X X 
Urine Drug Screen  Xf  X   
Physical Examination  and ECG    X X  
Vital Signs    X X  
Biochemistry, Hematology , and 
Urinalysis Samples   X X  
Weight and  Waist Circumference   X X X X 
Adverse Event  Monitoring  X X X X 
Concomitant Medication Review   X X X X 
C-SSRSg  X X X X 
Psychiatric/ Quality of Life Assessments  
CGI-S  X X X X 
IWQOL -Lite   X X  
Other/ General Procedures  
Study Drug Dispensation  X X X   
Study Drug Return Review   X X X  
Abbreviations: CGI -S=Clinical Global Impressions -Severity; C -SSRS=Columbia -Suicide Severity Scale; 
ECG=electrocardiogram; EOT=e nd of treatment; ET=early termination; IWQOL -Lite=Impact of Weight on 
Quality of Life-Lite 
a A visit window of ±4 days is allowed throughout the treatment p eriod and the Follow -up period.  
Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0 CONFIDENTIAL  
Page 20 of 49 b Subjects may be treated  with study drug for 24 to 48 months, or until regulatory action; duration will vary by 
[CONTACT_1130] . 
c Visit [ADDRESS_1173511] occur within 7  days of the EOT visit of the antecedent studies ( ALK3831- A304 , ALK3831- A306, or 
ALK3831- A307) and m
ay occur on the same day. Subsequent visits are to be conducted every month (every 
28 days [ ±4 days
]). 
d Except for every 3rd visit from Visit 1 (Quarterly Visits).  
e To be performed one  month (28  days [±4 days]) after the EOT/ET visit.   
f The urine drug screen will be performed at Visit 1; however if Visit 1 is the same as EOT visit of the antecedent 
study and a urine drug screen was already performed during that visit, it doesn’t need to be repeated . 
g ‘Since Last Visit’ version to be used at all indicated visits.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173512] by [CONTACT_9532] (PI)  or designated study personnel as outlined in Section  17.3. 
Prior to the administration of any study -specific procedures, authorized study personnel will 
obtain written  informed consent/assent as per local requirements from each potential subject as 
specified in Table 3. 
8.3.2. Eligibility Review  
An eligibility review will be conducted by [CONTACT_844322] [ADDRESS_1173513] inclusion criteria in Section 7.1 and  exclusion criteria in Section  7.2.  
8.3.3. Demographics and Medical  / Psychiatric  History  
Subject ’s demographic data and medical / psychiatric history (including primary psychiatric 
diagnosis) will 
be carried over from the antecedent studies ( ALK3831- A304 , ALK3831- A306, 
or ALK3831- A307 ). 
8.3.4. Concomitant
 Medica
tion Review  
At the time points specified in Table 3, subjects will be asked about the medications they have 
taken since their last visit , including prescription and nonprescription medications, vitamins, and 
supplements. 
The investigator will record the following data on all me dications used by [CONTACT_423]: name, 
dose, regimen, route of administration, start and stop dates, and the indication for use. 
8.3.5. Vital Signs  
Vital signs (ie, blood pressure, pulse, respi[INVESTIGATOR_697], and oral body temperature ) will be 
assessed at the timepoints specified in Table 3. An effort will be made to consistently use the 
same arm (preferably the subject’s dominant arm) to measure blood pressure and heart rate 
throughout the study. The blood pressure cuff will be calibrated per study site standard operati ng 
procedures. Automated measurement is preferred, but if performed manually, heart rate will be 
measured in the br achial artery for at least [ADDRESS_1173514] 5 minutes. Vital signs may be collected at any time during a scheduled visit, unless otherwise noted. 
8.3.6. Physical Examination 
A brief physical examination and an ECG (local) will be performed at the timepoints specified in 
Table 3. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173515] s should remove all personal items (including shoes, watches, and jewelry) and they 
should be weighed on the same scale for each measurement under the same conditions. 
Both weight and waist circumference will be measured three consecutive times at each 
assessment and all measurements will be recorded in the eCRF.  
8.3.8. Structured Interviews and Questionnaires  
Brief descriptions of each of the interviews and questionnaires to be distributed are available 
below. All interviews and questionnaires will be administere d by [CONTACT_582460]. 
For assessments performed at multiple visits, every effort should be made to pair the same 
clinician  / rater with the same subject across visits.  
Table 3 provides information on the timepoints at which each assessment should be 
administered.  
[IP_ADDRESS]. Safety Assessments 
[IP_ADDRESS].1. Columbia -Suicide Severity Rating Scale  
The PI [INVESTIGATOR_844311] C -SSRS according to the time points in Table 3. The “Since 
Last Visit” version of the C -SSRS will be used at all indicated visits . The C -SSRS should be 
administered by a qualified clinician trained in assessing and managing suicidal ideation and 
behavior ( Posner et al, 2011). 
[IP_ADDRESS]. Psychiatric/ Quality of Life Assessments  
[IP_ADDRESS].1. Clinical Global Impressions -Severity  
The PI o r designee will complete the CGI -S scale at the timepoints specified in Table 3. The 
CGI-S measures mental illness severity. Clinicians are asked to rate subjects based on their prior 
experience working with individuals in a similar patient population (Guy 1976). 
[IP_ADDRESS].2. Impact of Weight on Quality of Life- Lite 
Subjects will comp lete the IWQOL -Lite questionnaire (Kolotkin et al, 2001 ) at the timepoints 
specified in Table 3. 
8.3.9. Laboratory Assessments 
[IP_ADDRESS]. Drug Testing  
A urine drug test for opi[INVESTIGATOR_667868], including amphetamine/methamphetamine, 
phencyclidine, and cocaine , will be performed at the time points specified in Table 3. Results 
must be negative for the subject to be eligible for the study.  The urine drug screen will be 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 23 of 49 performed at Visit 1; however if Visit 1 is the same as the end of treatment visit of the antecedent 
study and a urine drug screen was already performed during that visit, it doesn’t need to be 
repeated. The urine drug screen may be repeated at any point during the study based on the 
investigator’s discretion.  
[IP_ADDRESS]. Hematology, Biochemistry, and Urinalysis 
Blood and urine samples for laboratory assessments will be collected at the timepoints specified in Table 3. Specific hematology, biochemistry, and urinalysis assessments are listed in Table 4. 
Subjects will be instructed not to eat or drink anything (except water) for 8 hours before each 
visit where blood samples for biochemistry and hematology assessments will be collected. 
Samples will be collected in accordance with the site’s usual procedures and analyzed by a 
central laboratory . Laboratory assessments  may be repeated at the Investigator’s  discretion . 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 24 of 49 Table 4: Clinical Laboratory Assessm ents 
Hematology Biochemistry  Urinalysis  
Hematocrit  
Hemoglobin 
Platelets  
Red blood cell count 
Total and differential (absolute) 
white blood cell count  General Chemistry  
Albumin 
Bicarbonate Calcium  
Chloride Creatine phosphokinase 
Glucose 
Lactic dehydrogenase 
Potassium 
Sodium 
Total protein  
Uric acid  
Endocrine Function Test  
HbA1c  
Prolactin  
Insulin 
Liver Function Tests  
Alanine aminotransferase  
Alkaline phosphatase  
Aspartate aminotransferase  
Gamma -glutamyl transferase  
Total bilirubin  
Renal Function Tests 
Blood urea nitrogen Creatinine  
Lipid Panel 
High -density lipoprotein 
Low-density lipoprotein 
Total cholesterol  
Triglycerides  Bilirubin  
Color and appearance  
Glucose Ketones 
Leukocytes 
Nitrite  
Occult blood pH Protein  
Specific gravity  
Urobilinogen 
Cotinine  
Microscopic examination of 
sediment, only if urinalysis 
dipstick results are abnormal  
 
 
[IP_ADDRESS]. Urine Pregnancy Testing  
A urine pregnancy test will be administered to all women at the time points specified in Table 3. 
At Visit 1, results must be negative for the subject to be eligible for the study. As highlighted in 
Section  7.3, a positive pregnancy test result at any time will necessitate the subject’s immediate 
withdrawal from the study. Additional follow- up may be necessary as indicated in  Section  8.4.1. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 25 of 49 8.3.10. Drug Dispensation and Reconciliation 
Section  9 provides information related to drug dispensing procedures. Study drug will be 
dispensed/administered  at the time points specified in Table 3. The study drug use and storage 
information  will be explained to/reviewed with the subject.  
8.3.11. Emergency Treatment Card  
An emergency treatment card will be distributed to each subject at Visit 1 and collected at the 
EOT/ET Visit. The card will indicate that the subject is receiving an opi[INVESTIGATOR_844312] t and 
olanzapi[INVESTIGATOR_530715]’s contact [CONTACT_3031], a suggested pain management plan and information regarding opi[INVESTIGATOR_249694]. Subjects will be instructed to keep the card with them at all times. Study personnel will confirm that subjects have  the card in their possession at each 
study visit.  
8.3.12. Adverse Event Monitoring  
All AEs will be monitored continuously from the time a subject signs the informed consent 
document until the completion of the final study visit (see Table 3). All AEs ongoing at the end 
of trial or concomitant medications continuing from the antecedent study will be carried over and followed until resolution. All AEs and serious adverse events (SAEs) are defined in Section  13.[ADDRESS_1173516] dose of study drug, unless they are surgically  sterile or postmenopausal (see below). 
The following are considered acceptable methods of contraception: 
1. Intrauterine device  
2. Oral contraceptive pi[INVESTIGATOR_229370] (eg, a vaginal ring, contraceptive patch, contraceptive implant)  
3. Double-barrier protection (eg, a condom with spermicide or a diaphragm with 
spermicide)  
4. Abstinence (see below)  
Subjects who are abstinent are eligible, provided they agree to use an acceptable contraceptive method should they become sexually active. Abstin ence is defined as “true abstinence” in which 
subjects must refrain from heterosexual intercourse for the full duration of the study and must be 
in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, 
ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of 
exposure to the study drug, and withdrawal are not acceptable methods of contraception. 
Subjects who are surgically sterile are exempt from the requirement to use contracept ion. 
Women who have undergone a hysterectomy, bilateral tubal ligation, or bilateral 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173517] be submitted to Alkermes via  
(per Section  13.6)  immediately, within 24 hours of awareness of the pregnancy, irrespective of 
whether an AE has occurred. The pregnancy will be followed until completion or termination. If the outcome of the pregnancy meets the criteria for classification as an SAE, it should be reported following the SAE procedure (see Section  13.6).  
8.4.2. Prohibited Medications  
In this study, the medications listed below are prohibited: 
• Antipsychotic medications for any indication  
• Diabetes treatments and hypoglycemic agents including Metformin and Insulin  
• Moderate to strong inhibitors or inducers of cytochrome P450 (CYP) 3A (prescription 
medications, OTC medications, or dietary supplements) within 30 days before 
enrollment through F ollow -up ( refer to  Section  [ADDRESS_1173518] of CYP3A inhibitors and 
inducers) 
• Use of opi[INVESTIGATOR_40500], including naltrexone (any formulations) and naloxone 
• Opi[INVESTIGATOR_844313] a subject’s participation in this study.  
8.4.3. Permitted Medications  
In this study, the medications listed below are permitted : 
• Medications that exhibit drug interaction potential with olanzapi[INVESTIGATOR_050], including known 
inhibitors and inducers of CYP1A2 ( Section  21), may affect olanzapi[INVESTIGATOR_667870]. Hence, investigators must use caution with inhibitors and inducers of 
CYP1A2 and monitor for need for study drug dose adjustment 
• Medicinal products known to be associated with increase in QTc interval should be 
used with caution given the increased risk of torsade de pointes ( Section  22) 

  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 27 of 49 • Oral contraceptive pi[INVESTIGATOR_229370] (eg, a vaginal ring, 
contraceptive patch, contraceptive implant) will be permitted  
• Permissible medications to treat extrapyramidal symptoms may include benzodiazepi[INVESTIGATOR_1651], antihistamines, and anticholinergics. Benzodiazepi[INVESTIGATOR_844314]- emergent akathisia 
• Treatment of agitation and/or anxiety with benzodiazepi[INVESTIGATOR_249704]  
8.4.4. Pain Management 
Because ALKS  [ADDRESS_1173519] should include the following: 
• Regional analgesia or use of non -opi[INVESTIGATOR_2467] 
• If opi[INVESTIGATOR_182023], the subject should be continuously 
monitored, in an anesthesia care setting, by [CONTACT_182107]. The opi[INVESTIGATOR_844315], specifically the establishment and the 
maintenance of a patent airway and assisted ventilation  
• Close monitoring by [CONTACT_182108] a setting equipped and staffed for cardiopulmonary resuscitation 
For subjects requiring emergency opi[INVESTIGATOR_182025], the study drug should not be administered. If opi[INVESTIGATOR_182026], it may take 
several days for opi[INVESTIGATOR_182027], since samidorphan functions as a μ-opi[INVESTIGATOR_844316]- mediated pain management.  
8.4.5. Fasting  
Subjects are required to fast for at least 8  hours (no food or drink except water) prior to 
laboratory blood draws. 
8.4.6. Other Restrictions and Requirements  
Additional restrictions and requirements include: 
• Prohibited substances include opi[INVESTIGATOR_2438], amphetamines (including methamphetamine), 
cocaine, and phencyclidine 
• Subjects will be required to abstain from blood or blood product donation during the study and for 30 days following the follow-up visit 
• Subjects will be instructed to maintain their normal caffeine intake and/or tobacco use as well as normal activity/exercise throughout the study. Subjects will be asked to 
abstain from strenuous physical activity  for 48  hours prior to each study visit 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 28 of 49 • Subjects will be asked to refrain from driving, operating machinery, or engaging in 
hazardous activities until they and the investigator are sure the study drug is not 
impairing their judgment and/or ability to perform skilled tasks  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 29 of 49 9. TREATME NT OF SUBJECTS  
9.1. Study Drug Dose and Administration  
The s tudy drug , ALKS  3831 will be available in the following doses: 
• ALKS  3831 5/10, 10/10, 15/10, and  20/10 administered as a coated bilayer tablet 
Subjects enrolled in the study will be started on the same olanzapi[INVESTIGATOR_844310]. Subjects may be titrated to a different dose after 
the start of the study at the Investigator’s discretion. Dosing will be flexible throughout the 
study; however, frequent adjustments are discouraged. Dose adjustments will only be performed 
on-site at the study center.  
Subjects will be given study drug to take home and instructed to take one tablet orally preferably at bedt ime. If there are tolerability problems, dosing may be switched to another time based on 
the judgment of the Investigator; frequent switching is discouraged. 
Subjects will be instructed to keep all unused tablets in their blister card and to return unused 
tablets to the study site at their next visit. If dosing is to occur at that visit, the dose should be taken from the subject’s next blister card, not fr om the card they are returning.  
If a dose is missed or forgotten, subjects will be instructed to resume regular dosing the following night. Subjects will be instructed not to take a double dose to try to “make up” for the missed dose. 
9.2. Treatment Adherence  
Subjects will undergo a study drug adherence review at the timepoints indicated in Table 3. 
Subjects will be instructed to keep all unused tablets in their original containers and to return the 
original containers with any unused study drug at each visit following dispensation. Study drug accountability will be documented as the number of tablets dispensed, dosed, lost/missing, or 
remaining. If applicable, the site will discuss non -adherence with the subject.  
9.3. Randomization/Method of Assigning Subjects to Treatment  
Not applicable.  
9.4. Blinding  
Not applicable.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173520] will be supplied as a coated bilayer tablet in four fixed-dose 
combinations: 
• ALKS  3831 5/10 (5 mg olanzapi[INVESTIGATOR_050]/10 mg samidorphan) 
• ALKS  3831 10/10 (10 mg olanzapi[INVESTIGATOR_050]/10 mg samidorphan) 
• ALKS  3831 15/10 (15 mg olanzapi[INVESTIGATOR_050]/10 mg samidorphan) 
• ALKS  3831 20/10 (20 mg olanzapi[INVESTIGATOR_050]/10 mg samidorphan) 
The tablets contain olanzapi[INVESTIGATOR_249674] L -malate (RDC -0313-02), and the following 
excipi[INVESTIGATOR_667872]: microcrystalline cellulose, lactose 
monohydrate, crospovidone, colloidal silica dioxide, and magnesium stearate. 
The tablet coating contains hydroxypropyl methylcellulose 2910 (HPMC 2910), titanium 
dioxide, lactose monohydrate, and triacetin as well as one or more of the following dye components; iron oxide yellow, iron oxide red, and/or FD&C blue #2/indigo carmine AL. 
10.2. Packaging and Labeling  
ALKS  [ADDRESS_1173521] should be stored at no more than 25°C. 
Under the US Controlled Substances Act, samidorphan is considered a Schedule II substance 
because it is derived from opi[INVESTIGATOR_174494]. Therefore, ALKS [ADDRESS_1173522] the drug movement records during the study and/or at the end of the study. 
Refer to Section  8.3.[ADDRESS_1173523] 
be destroyed. Packages may be destroyed on site according to Good Clinical Practice (GCP) and 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173524] party vendor 
operating in accordance with GCP  and/or Good Manufacturing Practice (GMP), as applicable. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173525] experience. 
11.1. Efficacy Endpoints  
• Change from baseline in CGI- S by [CONTACT_765] 
• Time to discontinuation  
• Change from baseline in IWQOL- Lite score by [CONTACT_667899], Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 33 of 49 12. ASSESSMENT OF PHARMACOKINETICS  
Not applicable.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 34 of 49 13. ASSESSMENT OF SAFETY 
Safety will be assessed on the basis of:  
• AEs (including clinically significant abnormal ECG findings)  
• Vital signs (oral temperature, respi[INVESTIGATOR_697], blood pressure, and heart rate) 
• Weight and waist circumference  
• Clinical laboratory p arameters ( biochemistry, hematology, and urinalysis) 
• C-SSRS results  
13.1. Safety Endpoints  
• Incidence of AEs  
• Percent change from baseline in body weight by [CONTACT_765] 
• Absolute change from baseline in body weight by [CONTACT_765] 
• Change from baseline in waist circumference by [CONTACT_765] 
13.2. Definition of Adverse Event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject who has 
been administered a pharmaceutical product. The occurrence, which may or may not have a 
causal relationship with the investigational treatment, may include any clinical or laboratory change that does not commonly occur in that subject and is considered clinically significant. 
Illnesses present prior to the subject signing the informed consent form (ICF) are considered to 
be pre-existing conditions and are documented on the medical history eCRF. Pre- existing 
conditions that worsen during the study are entered on the AE eCRF. 
All out-of- range laboratory values will be deemed as clinically significant or not clinically 
significant by  [CONTACT_737]. Clinically significant values will be considered AEs and will be 
recorded as such on the eCRFs.  
Pregnancy is not considered an AE, although a subject will be withdrawn from the study if a 
pregnancy occurs. As described in Section  8.4.1, the pregnancy, including a partner’s pregnancy, 
must be reported to Alkermes, and additional follow-up may be required.  
Transition from schizophreniform to schizophrenia is not considered an AE unless deemed so by 
[CONTACT_737].  
13.3. Definition of Serious Adverse Event  
An SAE is any AE, occurring at any dose and regardless of causality, that: 
• Results in death  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 35 of 49 • Is life -threatening. The subject is at immediate risk of death from the reaction as it 
occurs. This does not include reaction that, had it occurred in a more severe form, 
might have caused death  
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Results in persistent  or significant disability/incapacity (eg, a substantial disruption of 
a person’s ability to conduct normal life functions) 
• Is a congenital anomaly/birth defect  
Important medical events that may not result in death, be immediately life threatening, or requ ire 
hospi[INVESTIGATOR_182032], based upon appropriate medical judgment, they may jeopardize the patient or subject and may require intervention to prevent one of the other outcomes listed above. Admission to an inpatient unit or hospi[INVESTIGATOR_34092] a nonmedical or 
nonbehavioral reason (ie, social stay admission) during the study in the absence of untoward 
medical occurrence will not be considered an SAE, but will be reported as an AE. 
Hospi[INVESTIGATOR_844317].  
13.4. Relationship to Study Drug  
The assessment of study drug relationship to each AE will be reported on the appropriate source 
document (and SAE form, in the event of an SAE) by [CONTACT_737] (or designated 
Sub-Inv estigator) according to his/her best clinical judgment. The criteria listed in Table [ADDRESS_1173526] be present to be 
indicative of a particular drug relationship. All study drugs are considered “test drugs” for the 
purposes of the definitions listed in the table. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 36 of 49 Table 5: Adverse Event Causality Guidelines  
Relationship  Criteria for assessment  
Definitely related  There is evidence of exposure to the test drug.  
AND  
The temporal sequence of the AE onset relative to administration of the test drug is 
reasonable.  
The AE is more likely explained by [CONTACT_182109]. 
Dechallenge (if performed) is positive.  
Rechallenge (if feasible) is positive.  
The AE shows a pattern consistent with previous knowledge of the test drug or test drug class.  
Probably related  There is evidence of exposure t o the test drug. 
AND  
The temporal sequence of the AE onset relative to administration of the test drug is reasonable.  
The AE is more likely explained by [CONTACT_182109]. 
Dechallenge (if performed) is positive.  
Possibly related  There is  evidence of exposure to the test drug. 
AND  
The temporal sequence of the AE onset relative to administration of the test drug is 
reasonable.  
The AE could have been due to another equally likely cause. 
Dechallenge (if performed) is positive.  
Probably not 
related  There is evidence of exposure to the test drug.  
AND  
There is another more likely cause of the AE.  
Dechallenge (if performed) is negative or ambiguous.  
Rechallenge (if performed) is negative or ambiguous.  
Definitely not 
related  The subject did not receive the test drug.  
OR 
Temporal sequence of the AE onset relative to administration of the test drug is not 
reasonable.  
OR 
There is another obvious cause of the AE.  
Abbreviations: AE=adverse event  
13.5. Monitoring and Recording of Adverse Events  
All AE data collection will begin after a subject signs the ICF  and will continue until completion 
of the safety follow -up visit . Any AE or SAE having an onset after the safety follow -up visit will 
  Al ker mes, I nc.  
Pr ot oc ol A L K [ADDRESS_1173527] u g (s ee 
Secti o n  1 3. 4 ), t he i nte nsit y (se v erit y) of t he e ve nt, acti o n ta ke n, a n d s u bject o utc o me. 
T he f oll o wi n g criteri a s h o ul d be use d t o g ui de t h e assess me nt of i nte nsit y (se verit y): 
• Mil d:  Ca uses a ware ness of si g n or s y m pt o m, b ut is easil y t oler ate d; d oes n ot i nterfere 
wit h us ual acti vities  
• M o der ate:  Ca uses disc o mf ort e n o u g h t o i nterfere wit h us ual acti vities  
• Se vere:  Is i nca p acitati n g; res ults i n i na bilit y t o w or k or perf or m us ual acti vities  
All A Es will be f oll o we d u ntil res ol uti o n, u ntil dee me d sta ble b y t he I n v esti gat or , or u ntil t he 
s u bject is dee me d b y t he I n v esti gat or t o be l ost t o f oll o w- u p. 
F or cli nical st u d y safet y r e p orti n g p ur p oses, t he m ost rece nt versi o n of t he I n vesti gat or’s 
Br oc h ure will be use d as t he ref ere n ce d oc u m e nt t o desi g nat e e ve nt e x pecte d ness.  
Wit h dra wal fr o m t he st u d y as a res ult of a n A E, a n d a n y t h era p e utic meas ures t hat ar e ta ke n , 
s hall be at t he discreti o n of t he I n vesti gat or. If a s u bject wit h dra ws fr o m t he st u d y f or a n y r eas o n , 
a n y o n g oi n g A Es will be f oll o we d u ntil res ol uti o n, u ntil dee me d sta ble b y t he I n vesti gat or, or 
u ntil t he s u bject is dee me d b y t he I n vesti gat or t o b e l ost t o f oll o w - u p. 
[ADDRESS_1173528] be re p ort e d t o  
i m me di atel y , wit hi n 2 4 h o urs of disc o ver y, b y e m aili n g  or f a xi n g t he re p ort t o t he 
f oll o wi n g:  
Atte nti o n:   Me dical M o nit or  
U S E m ail:  
R O W E m ail:  
U S F a x N u m ber:   
R O W F a x N u m ber:   
T he writte n re p ort s h o ul d be s u b mitte d o n t he S A E f or m pr o vi de d f or t his p ur p ose. T he r e p ort 
m ust i ncl u de t he I n v esti gat or ’s o pi [INVESTIGATOR_9384] o n as t o w het her t he e v e nt is st u d y dr u g -relate d. If t his 
relati o ns hi p is deter mi ne d t o be p ossi bl y, pr o ba bl y, or d efi nitel y relat e d t o st u d y dr u g, e vi d e nce 
t o s u p p ort t his assess me nt m ust als o be pr o vi de d.  
T he writte n re p ort f or pr e g na n cies i n fe m ale s u bjects a n d i n fe male p art ners of male  s u bjects 
s h o ul d be s u b mitte d o n t he Pre g na nc y R e p ort F or m pr o vi de d f or t his p ur p ose. P P D 
P P D 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 38 of 49 14. STATISTICS  
14.1. Sample Size Considerations  
No formal sample size calculation will be performed for this extension study. A sample size of 
approximately 500 subjects is based o n the estimated number of subjects who are expected to 
roll over from the antecedent Phase 3 studies within 7  days  (ALK3831- A304 , ALK3831- A306, 
and ALK3831- A307 ). 
14.2. General Statistical Methodology  
The statistical analysis methods are described below. Additio nal details will be provided in the 
Statistical Analysis Plan  (SAP)  to be finalized bef ore database lock . 
In general, summary statistics (n, mean, standard deviation, median, minimum and maximum for continuous variables, and number [%] of subjects in each category for categorical variables) will 
be provided for all variables.  
Source data for the summary tables and statistical analyses will be presented as subject data listings.  
14.2.1. Study Populatio n 
[IP_ADDRESS]. Safety Population 
The safety population will include all enroll ed subjects who receive at least one dose of study 
drug. All analyses will be conducted using the safety population. 
14.3. Demographics and Baseline Data  
Demographics and baseline characteristics such as gender, age, race, weight, and body mass 
index will be summarized . 
14.4. Efficacy Analyses 
Changes from baseline in CGI-S and IWQOL- Lite scores will be summarized using descriptive 
statistics.  The time to discontinuation will be estimated using the Kaplan -Meier (KM) method 
and the KM plot will be provided. 
14.5. Pharmacokinetic  Analyses 
Not applicable.  
14.6. Safety  and Tolerability Analyses 
All safety assessments will be summarized using descriptive statistics. All safety analyses will be 
based on observed data only, and no missing values will be imputed.  Safety will be evaluated 
based on the occurrence of AEs  (including clinically significant abnormal ECG findings) , vital 
signs, and results of clinical laboratory tests. Reported AE terms will be coded using the MedDRA preferred terms and system organ classes.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 39 of 49 Treatment -emergent AEs (TEAEs) are defined as AEs that occur or worsen  after the first dose of 
study drug. 
The summary tables will include the number and percent of subjects with TEAEs by [CONTACT_29974], and by [CONTACT_229410]. All SAEs, TE AEs leading to 
discontinuation, as well as additional categories of AEs as defined in the SAP will be 
summarized. The number and percentage of subjects with TEAEs will also be summarized by 
[CONTACT_373436]. 
Observed values and change from baseline in laboratory parameters  and vital signs  will be 
summarized by [CONTACT_765].  
The number and percentage of subjects who have met potentia lly clinically significant criteria at 
any postbaseline visit will be summarized for laboratory  and vital signs. Supporting listings will 
be provided. The number and percentage of subjects with C-SSRS assessments of suicidal ideation and 
behavior will also be summarized.  
Concomitant medications will be summarized by W orld Health Organization (WHO) 
Anatomical  Therapeutic Chemical ( ATC ) classification system. Listings will be provided for all 
concomitant medications.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173529] ACCESS TO SOURCE DATA/DOCUMENTS  
15.1. Study Monitoring  
Monitoring of the study site (including, but not limited to, reviewing eCRFs for accuracy and 
completeness) will be performed by [CONTACT_249738]. 
15.2. Audits and Inspections  
By [CONTACT_12142], the Investigator agrees that, within local regulatory restrictions and 
institutional and ethical considerations, authorized representatives of Alkermes, a regulatory 
authority, and/or an i nstitutional review board (IRB)/ independent e thics committee (IEC) may 
visit the site to perform audits or inspections, including the drug storage area, study drug stocks, 
drug accountability records, subject charts , source documents, and other records relative to study 
conduct. The purpose of an Alkermes audit or inspection is to systematically and independently 
examine all study -related activities and documents (eg, laboratory reports, x-rays, workbooks, 
subjects’ medical records) to determine whether these activities were conducted, and data recorded, analyzed and accurately reported , according to the protocol, GCP guidelines of the 
International Council on Harmonisation (ICH), and any applicable regulatory requirements.  
The I nvestigator should contact [CONTACT_182118] a regulatory agency 
regarding an inspection. 
15.3. Institutional Review Board/Independent Ethics Committee  
The investigator must obtain IRB/IEC approval for the investigation. Initial IRB/IEC approval , 
as well as all materials approved by [CONTACT_1201]/IEC for this study, including the subject consent 
form and recruitment materials, must be maintained by [CONTACT_72037]. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173530] be based on source documents or approved to be 
the original data (ie, data directly reported on the eCRF). All eCRFs will be completed by [CONTACT_182119]. 
The Alkermes monitor or designated representative will review all source records on -site and 
compare them to the data  collected on the eCRF . 
16.2. Confidentiality of Data  
By [CONTACT_12570], the Investigator affirms to Alkermes that he or she will maintain in 
confidence information furnished to him or her by [CONTACT_582473]. All data will be considered the sole property of Alkermes. Please refer to the Clinical 
Study Agreement (CSA) for details.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 42 of 49 17. ETHICAL C ONSIDERATIONS  
17.1. Ethics Review  
The clini cal site’s IRB/IEC must meet all relevant regulatory requirements. The study protocol 
and ICF will be reviewed by [CONTACT_1201]/IEC prior to enrolling subjects into the study; written 
approval from the committee must be received by [CONTACT_182121] . The protocol must be re-approved by [CONTACT_1201]/IEC upon receipt of amendments 
and annually, as local regulatory requirements require.  
The Investigator is responsible for submitting all protocol changes and SAE reports to the 
IRB/ IEC according to local procedures. At a minimum, all SAEs requiring an investigational 
new drug safety report must be immediately reported.  
All relevant correspondence from the IRB/IEC will be forwarded by [CONTACT_12566] a time ly fashion. 
17.2. Ethical Conduct of the Study  
This study will be conducted in accordance with the protocol, the ICH Guideline E6, and all 
applicable local regulatory requirements. Good Clinical Practice (GCP)  is an international ethical 
and scientific quality s tandard used for designing, conducting, recording, and reporting studies 
involving the participation of human subjects. Alkermes is committed to complying with this standard to provide assurance that the rights, safety, and well-being of study subjects wil l be 
protected, consistent with the principles having their origin in the Declaration of Helsinki. 
17.3. Written Informed Consent  
The I nvestigator (or authorized designee) at each center will ensure that the subject and 
parent/caregiver (as per local requirements or the subject’s legal representative) is given full and adequate oral and written information about the nature, purpose, potential and possible risks and 
benefits of the study. Each prospective subject and parent/caregiver (as per local requirements) 
will receive an IRB-approved ICF that summarizes the pertinent study information and will be 
given ample time to read the form and ask questions about the study. All information is to be 
provided in a language understandable to the subject and must not include any language that 
waives the subject’s legal rights. Prospective subjects must also be informed of their right to 
withdraw consent without prejudice at any time during the study. If the subject chooses to 
participate, he/she must sign the ICF /assent form (as per local requirements)  and if required, the 
parent/caregiver must sign the parent/caregiver ICF before any study- specific procedures are 
conducted. 
All subjects will be informed of their rights to privacy and will be made aware that the study data 
will be submitted to Alkermes,  the IRB, the contract research organization (CRO) , if applicable, 
and to regulatory authorities for review and evaluation for the duration of the study and until the 
project has been approved for marketing, or is withdrawn from investigation. They will also be 
informed that the study monitor may inspect their medical records to verify the accuracy and completeness of the study records and results. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.[ADDRESS_1173531] safety information may require a revision of the 
ICF/assent for m, which must be reviewed and approved by [CONTACT_1201], and then signed by [CONTACT_844323].  
The time that informed consent is obtained must be documented. The Investigator must maintain the original, signed ICF /assent form  in the subject’s source documents. A copy of the signed 
ICF/assent form  must be given to the subject. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 44 of 49 18. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_182035]; please refer to the C SA for further details.  
18.1. Data Capture  
As stated in Section  16.1, this study will use eCRFs for capturing data. All entries, corrections, 
and alterati ons will be made by [CONTACT_12556]. A ll data 
entries will be verified for accuracy and correctness  by [CONTACT_12557] . The electronic 
data capture system maintains a full audit trail.  
A paper copy of all laboratory reports will remain with the source documents at the study site. All electronic source data collected outside of the eCRF, such as e -diaries, central laboratory, or 
central MRI data, will be transferred directly to EDC or dir ectly to Alkermes for incorporation 
into the final datasets. All out-of- range laboratory values will be deemed as clinically significant 
or not clinically significant by [CONTACT_737] . Clinically significant values will be considered 
AEs and will be recorded as such on the eCRFs . 
All AEs will be coded using MedDRA. Concomitant medications will be categorized using the 
WHO- ATC classification system.  
18.2. Inspection of Records  
Alkermes or its representative will be allowed to conduct site visits to the investigational 
facilities for the purpose of monitoring any aspect of the study. The Investigator agrees to allow 
the monitor to inspect the drug storage area, study drug stocks, drug accountability records, subject charts and source documents, and other records relative to study conduct. 
18.3. Retention of Records 
Retention and storage of all essential clinical study documents shall be governed by [CONTACT_229417]’s CSA and in accordance with ICH guidelines/local regulatory 
requirements as follows: 
Essential documents should be retained until at least [ADDRESS_1173532]. These documents should be retained for a 
longer period, however, if required by [CONTACT_203890]. I t is the responsibility of the Sponsor to inform the Investigator/Institution as to when 
these documents no longer need to be retained. 
Subjects’ medical files should be retained in accordance with the applicable legislation and in 
accordance with the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], institution, or private practice.  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 45 of 49 18.4. Use of Information and Publication Policy  
Data generated in this study are proprietary information that are the sole property of Alkermes. 
Results of the study are to be held in confidence by [CONTACT_721676]. 
Please refer to the CSA for details on the procedures for publishing and presenting data. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 46 of 49 19. REFERENCES  
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive 
research synthes is. Am J Psychiatry. 1999;156(11):1686-1696. 
Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 
2010;36(1):71-93. doi: 10.1093/schbul/sbp116. 
Corre ll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-epi[INVESTIGATOR_667876]: baseline results from the RAISE- ETP study. JAMA 
Psychiatry. 2014;71(12):1350-1363. doi: 10.1001/jamapsychiatry.2014.1314. 
Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, 
Inhibitors and Inducers. 2016; http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. Accessed on 08 Sep 2017. 
Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of 
Health, Education, and Welfare; 1976. Kolotkin RL, Crosby [CONTACT_135569], Kosloski KD, Williams GR. Development of a brief measure to assess 
quality of life in obesity. Obes Res. 2001;9(2):102-111. doi: 10.1038/oby.2001.13. 
Leucht S, Cipriani A, Spi[INVESTIGATOR_240454] L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple- treatments meta -analysis. Lancet. 2013;382(9896):951-962. 
doi: 10.1016/S0140-6736(13)[ZIP_CODE]-3. 
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients 
with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. 
Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treat ment on nonfasting 
triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res. 2008;103(1-3):104-109. 
doi: 10.1016/j.schres.2008.04.023. 
Posner K, Brown GK, Stanley B, et al. The Columbia- Suicide Severity Rating Scale: initial 
validity and inter nal consistency findings from three multisite studies with adolescents and 
adults. Am J Psychiatry. 2011;168(12):1266-1277. doi: 10.1176/appi.ajp.2011.10111704. 
University of Washington: School of Pharmacy. In Vivo CYP3A Inducers. Seattle, WA: M and 
T Drug  Interaction Database; 2017a.  
University of Washington: School of Pharmacy. In Vivo Inhibitors of CYP3A Probes. Seattle, WA: M and T Drug Interaction Database; 2017b. 
Wirshing DA, Wirshing WC, Kysar L, et al. Novel Antipsychotics: Comparison of Weight Gain 
Liabilities. J Clin Psychiatry. 1999;60(6):358-363. 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 47 of 49 20. APPENDIX A: PARTIAL LIST OF PROHIBITED 
CYTOCHROME P450 (CYP) 3A INHIBITORS AND INDUCERS  
The following is a list of CYP3A inhibitors and inducers that subjects are to avoid within 
[ADDRESS_1173533] is not comprehensive. 
Table 6: Partial List of CYP3A Inhibitors and Inducers 
Moderate -to-Strong Inh ibitors Moderate -to-Strong Inducers  
Aprepi[INVESTIGATOR_667878]/Ritonavira Bosentan  
Cimetidine  Itraconazole  Carbamazepi[INVESTIGATOR_667879]/R itonavira Enzalutamide 
Clotrimazole  Mibefradil  Etravirine  
Cobicistat Nefazodone Mitotane  
Conivaptan  Nelfinavir  Modafinil  
Crizotinib  Paritaprevir/R itonavir and 
(Ombitasvir and/or Dasabuvir)a Phenobarbital  
Cyclosporine  Posaconazole  Phenytoin 
Danoprevir/R itonavira  Ritonavira Rifabutin  
Diltiazem  Saquinavir/Ritonavira Rifampin  
Dronedarone Telaprevir  St. John’s Wort  
Elvitegravir/R itonavira Telithromycin  — 
Erythromycin  Tipranavir/R itonavira — 
Fluconazole  Tofisopam  — 
Fluvoxamine  Troleandomycin — 
Grapefruit Juice  Verapamil  — 
Imatinib  Voriconazole — 
a Ritonavir is usually given in combination with other anti -HIV or anti -HCV drugs in clinical practice. Caution 
should be used when extrapolating the observed effect of ritonavir alone to the effect of combination regimens on 
CYP3A activities  
Source: ( Food and Drug Administration 2016; University of Washington: School of Pharmacy 2017a ; University of 
Washingt on: School of Pharmacy 2017b)  
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 48 of 49 21. APPENDIX B: PARTIAL LIST OF  CYP1A2 MODERATE -
TO-STRONG INHIBITORS AN D MODERATE INDUCERS  
Table 7: Partial List of CYP1A2 Inhibitors and Inducers  
Moderate -to-Strong C YP1A2 Inhibitors  Moderate CYP1A2 Inducers  
Ciprofloxacina Oral Contraceptives Phenytoina 
Enoxacin Zafirlukast  Rifampi[INVESTIGATOR_667880] — Ritonavira 
Methoxsalen  — Teriflunomide 
Mexiletine  — Tobacco  
a These drugs are also known to be CYP3A inhib itors or inducers and are prohibited , as shown in Appendix A  
Source:  (Food and Drug Administration 2016) 
  Alkermes, Inc.  
Protocol ALK3831-A308 Amendment 3.0  CONFIDENTIAL  
Page 49 of 49 22. APPENDIX C: PARTIAL LIST OF MEDICATIONS KNOWN TO 
BE ASSOCIATED WITH PROLONGED QT C INTERVAL AND 
TORSADE DE POINTES 
The following is a list of medications known to be associated with t orsade de pointes. This list is 
not comprehensive. 
Table 8: Partial List of Medications Known to Be Associated with Prolonged QTc 
Interval and Torsad e de Pointes  
Generic Name  
[CONTACT_844324] L (Intra -coronary)  
Arsenic trioxide  Dronedaronea Pentamidine  
Azithromycin  Droperidolb Pi[INVESTIGATOR_667881] — 
Dofetilide  Ondansetron — 
a These drugs are also known to be CYP3A inhib itors or inducers and are prohibited , as shown in Appendix A  
b Antipsychotics (other than the study drug), drugs of abuse , and prescribed opi[INVESTIGATOR_667882]  